Dose-escalated abarelix in androgen-independent prostate cancer: A phase I study

Anti-Cancer Drugs

Volumn 17, Issue 9, 2006, Pages 1075-1079

  Beer, Tomasz M ^a   Ryan, Christopher ^a   Bhat, Gajanan ^b   Garnick, Marc ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Praecis Pharmaceuticals Incorporated   (United States)

Author keywords

Abarelix; Hormone antagonists; Prostate cancer

Indexed keywords

ABARELIX; ANDROGEN; FOLLITROPIN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN THERAPY; ANEMIA; ARTHRALGIA; ARTICLE; BONE PAIN; BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; FACIAL NERVE PARALYSIS; FOLLITROPIN BLOOD LEVEL; HEARING DISORDER; HUMAN; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; KRUSKAL WALLIS TEST; MALE; NECK PAIN; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRESYNCOPE; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; SPONDYLITIS; THORAX PAIN; URINE RETENTION; URTICARIA;

AGED; AGED, 80 AND OVER; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 33749005634     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000231476.84782.55     Document Type: Article

References (14)

1. Dirnhofer S, Berger C, Hermann M, Steiner G, Madersbacher S, Berger P. Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate 1998; 35:212-220.
2. Ben-Josef E, Yang SY, Ji TH, Bidart JM, Garde SV, Chopra DP, et al. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol 1999; 161:970-976.
3. Bhasin S, Berman N, Swerdloff RS. Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment. J Androl 1994; 15:386-391.
4. Huhtaniemi I, Venho P, Jacobi G, Rannikko S. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer. J Androl 1991; 12:46-53.
5. Mahler C, Verhelst J, Chaban M, Denis L. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue. Cancer 1991; 67:557-559.
6. Khan MS, O'Brien A. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int 1998; 60:33-40.
7. Garnick MB, Campion M. Abarelix depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Mol Urol 2000; 4:275-278.
8. Beer TM, Garzotto M, Eilers KM, Lemmon D. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. J Urol 2003; 169:1738-1741.
9. Wong SL, Lau DT, Baughman SA, Menchaca D, Garnick MB. Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. Clin Pharmacol Ther 2003; 73:304-311.
10. Wong SL, Lau DT, Baughman SA, Fotheringham N, Menchaca D, Garnick MB. Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. J Clin Pharmacol 2004; 44:495-502.
11. Padmanabhan V, Sharma TP. Neuroendocrine vs. paracrine control of follicle-stimulating hormone. Arch Med Res 2001; 32:533-543.
12. DePaolo LV, Bald LN, Fendly BM. Passive immunoneutralization with a monoclonal antibody reveals a role for endogenous activin-B in mediating FSH hypersecretion during estrus and following ovariectomy of hypophysectomized, pituitary-grafted rats. Endocrinology 1992; 130:1741-1743.
13. Schwall RH, Szonyi E, Mason AJ, Nikolics K. Activin stimulates secretion of follicle-stimulating hormone from pituitary cells desensitized to gonadotropin-releasing hormone. Biochem Biophys Res Commun 1988; 151:1099-1104.
14. Carroll RS, Kowash PM, Lofgren JA, Schwall RH, Chin WW. In vivo regulation of FSH synthesis by inhibin and activin. Endocrinology 1991; 129:3299-3304.